Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Jade Biosciences, Inc. (NASDAQ:JBIO) has earned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $51.75.

A number of analysts have weighed in on the stock. Wall Street Zen lowered shares of Jade Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. BTIG Research upped their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Wedbush reiterated an “outperform” rating and issued a $47.00 price target on shares of Jade Biosciences in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and set a $48.00 price objective on shares of Jade Biosciences in a report on Tuesday, August 11th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of Jade Biosciences in a research report on Thursday.

Institutional Trading of Jade Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new stake in Jade Biosciences during the 1st quarter worth approximately $43,557,000. Renaissance Technologies LLC raised its stake in shares of Jade Biosciences by 94.0% during the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock valued at $1,897,000 after acquiring an additional 65,438 shares during the last quarter. Stempoint Capital LP acquired a new position in shares of Jade Biosciences during the first quarter worth $2,164,000. Bank of New York Mellon Corp acquired a new position in shares of Jade Biosciences during the second quarter worth $1,896,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of Jade Biosciences in the fourth quarter worth $25,323,000.

Jade Biosciences Trading Down 2.0%

JBIO stock opened at $13.77 on Friday. The stock has a market capitalization of $875.77 million, a P/E ratio of -7.17 and a beta of 1.64. Jade Biosciences has a 12 month low of $8.16 and a 12 month high of $28.00. The firm has a 50-day moving average price of $19.58 and a 200-day moving average price of $19.74.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities analysts predict that Jade Biosciences will post -2.89 EPS for the current fiscal year.

Key Jade Biosciences News

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $55 price target, implying substantial potential upside from the reference price of $13.77. The bullish view provides positive sentiment and suggests the firm sees significant value in Jade’s pipeline.
• Positive Sentiment: Jade301 produced favorable preclinical results in dermatomyositis. The half-life-extended anti-IFN-? antibody demonstrated high-affinity and selective binding, greater functional potency than the dazukibart comparator in disease-relevant human cells, and an approximately 25-day half-life after subcutaneous dosing in non-human primates. Jade Biosciences Announces Preclinical Data Characterizing JADE301
• Positive Sentiment: JADE301 was well tolerated in non-human primates at all tested subcutaneous doses, with predictable distribution into muscle. Jade expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. Jade Biosciences Advances JADE301 Toward Phase 1 Trial
• Neutral Sentiment: The company discussed JADE301’s profile and data in a presentation, transcript, and webcast, increasing investor visibility but adding no new clinical efficacy evidence. JADE301 Program Profile and Preclinical Data Slideshow
• Negative Sentiment: JADE301 remains an early-stage, preclinical asset. The positive findings have not yet been validated in humans, and investors must wait for Phase 1 safety and pharmacokinetic data. This development risk may be weighing on JBIO despite the favorable research update and analyst target.

About Jade Biosciences

Jade Biosciences, Inc (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.